LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Analysis of Immune Cells Predicts Breast Cancer Prognosis

By LabMedica International staff writers
Posted on 20 Nov 2024
Image: The study findings suggest that tumor-infiltrating lymphocytes are a robust biomarker of breast cancer (Photo courtesy of Shutterstock)
Image: The study findings suggest that tumor-infiltrating lymphocytes are a robust biomarker of breast cancer (Photo courtesy of Shutterstock)

Tumor-infiltrating lymphocytes (TILs) are immune cells crucial in combating cancer. Their presence in a tumor indicates that the immune system is attempting to attack and eliminate cancer cells. TILs can be important indicators in predicting how patients with triple-negative breast cancer will respond to treatment and how the disease might progress. However, assessing these immune cells can yield inconsistent results. Artificial intelligence (AI) has the potential to standardize and automate this process, but proving its effectiveness for healthcare use has been challenging. Now, researchers have explored how different AI models can predict the prognosis of triple-negative breast cancer by analyzing specific immune cells within the tumor. This study, published in eClinicalMedicine, represents a significant step toward incorporating AI into cancer care to enhance patient outcomes.

Researchers at Karolinska Institutet (Stockholm, Sweden) tested ten different AI models to evaluate their ability to analyze tumor-infiltrating lymphocytes in tissue samples from patients with triple-negative breast cancer. The results revealed that the performance of the AI models varied, but eight out of the ten models demonstrated strong prognostic capability, meaning they could predict patient health outcomes with similar accuracy. Even models trained on smaller datasets showed promising results, suggesting that tumor-infiltrating lymphocytes are a reliable biomarker. The study highlights the need for large datasets to compare different AI models and validate their effectiveness before they can be used in clinical practice. Although the findings are promising, further validation is required.

“Our research highlights the importance of independent studies that mimic real clinical practice,” said Balazs Acs, researcher at the Department of Oncology-Pathology, Karolinska Institutet. “Only through such testing can we ensure that AI tools are reliable and effective for clinical use.”

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more